Antimony Excretion in a Patient with Renal Impairment During Meglumine Antimoniate Therapy
Authors:
- 1 September 2000
- journal article
- case report
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 20 (9) , 1141-1143
Abstract
Meglumine antimoniate was administered to a patient with visceral leishmaniasis with normal renal function. Soon after the first intramuscular administration of meglumine antimoniate 20 mg/kg, equivalent to 510 mg antimony (Sb), the patient developed septic shock with oliguria. Creatinine clearance decreased to 23 ml/minute. Treatment was discontinued, and Sb urinary excretion was measured. After the initial dose, 500.25 mg Sb was recovered in urine over 8 days, corresponding to 98% of the amount of Sb given intramuscularly (66% eliminated within first 48 hrs). Nine days after the dose, meglumine antimoniate was reintroduced at a dosage of 11.7 mg/kg (equivalent to 300 mg Sb) every 48 hours with good tolerance. At that time creatinine clearance had returned to 87.8 ml/minute. By day 14 of therapy the interval was reduced to daily administration of the same dose; the dosage was increased to 16.6 mg/kg/day (equivalent to 425 mg Sb) from day 17 to day 31. The patient eventually completely recovered and was discharged with normal renal function. Although no specific guidelines exist for dosage adjustment in renal failure, monitoring of Sb urinary excretion indicates that the kidneys are the almost exclusive route of elimination.Keywords
This publication has 7 references indexed in Scilit:
- Human biomonitoring of antimonyInternational Archives of Occupational and Environmental Health, 1998
- Avaliação da tolerância e nefrotoxicidade do antimonial pentavalente administrado na dose de 40mg Sb v/kg/dia, de 12/12h, por 30 dias na forma cutaneo-mucosa de leishmanioseRevista da Sociedade Brasileira de Medicina Tropical, 1997
- Human Leishmaniasis: Clinical, Diagnostic, and Chemotherapeutic Developments in the Last 10 YearsClinical Infectious Diseases, 1997
- Cytogenetic Observations After Meglumine Antimoniate Therapy for Visceral LeishmaniasisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1996
- Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniateTransactions of the Royal Society of Tropical Medicine and Hygiene, 1988
- RENAL TUBULAR DYSFUNCTION IN PATIENTS WITH MUCOCUTANEOUS LEISHMANIASIS TREATED WITH PENTAVALENT ANTIMONIALSThe Lancet, 1983
- RENAL CLEARANCE OF PENTAVALENT ANTIMONY (SODIUM STIBOGLUCONATE)The Lancet, 1980